{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"}],"title":"CR"},{"measurements":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"38"}],"title":"PR"},{"measurements":[{"groupId":"OG000","value":"204"},{"groupId":"OG001","value":"220"}],"title":"No response, progressive disease, not evaluable or not available"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"262"},{"groupId":"OG001","value":"262"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"Objective response rate includes all patients with either a complete response (CR) or a partial response (PR) to study treatment","groups":[{"description":"Margetuximab 15 mg/kg administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG000","title":"Margetuximab Plus Chemotherapy"},{"description":"Trastuzumab administered every 21 days with physician's choice of 1 of 4 backbone chemotherapy regimens.","id":"OG001","title":"Trastuzumab Plus Chemotherapy"},{"description":"Margetuximab with or without chemotherapy","id":"OG002","title":"Margetuximab Infusion Substudy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Tumor response was assessed for patients with measurable disease at baseline. The cutoff data for analysis corresponds with the completion of enrollment. Detection of ORR requires at least 12 weeks, so the ORR may be underestimated. Outcome measure is calculated only for the randomized study population. The 88 participants in the sub-study were not part of the efficacy population.","reportingStatus":"POSTED","timeFrame":"Tumor assessments are conducted every 6 weeks for the first 24 weeks and then every 24 weeks until progression of cancer, up to 6.5 years.","title":"To Evaluate the Objective Response Rate (ORR) as Determined by Independent Radiological Review.","type":"SECONDARY","unitOfMeasure":"Participants"}